BRISTOL-MYERS SQUIBB CO (BRM.DE) Stock Fundamental Analysis
FRA:BRM - Deutsche Boerse Ag - US1101221083 - Common Stock - Currency: EUR
Overall BRM gets a fundamental rating of 5 out of 10. We evaluated BRM against 52 industry peers in the Pharmaceuticals industry. BRM has only an average score on both its financial health and profitability. BRM has a decent growth rate and is not valued too expensively. BRM also has an excellent dividend rating.
1. Profitability
1.1 Basic Checks
In the past year BRM was profitable.
BRM had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: BRM reported negative net income in multiple years.
BRM had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of -9.66%, BRM is doing worse than 69.23% of the companies in the same industry.
With a Return On Equity value of -54.78%, BRM is not doing good in the industry: 75.00% of the companies in the same industry are doing better.
With a decent Return On Invested Capital value of 11.77%, BRM is doing good in the industry, outperforming 65.38% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for BRM is below the industry average of 13.62%.
The 3 year average ROIC (10.96%) for BRM is below the current ROIC(11.77%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -9.66% | ||
| ROE | -54.78% | ||
| ROIC | 11.77% |
ROA(3y)1.77%
ROA(5y)0.82%
ROE(3y)-2.38%
ROE(5y)-2.3%
ROIC(3y)10.96%
ROIC(5y)9.23%
1.3 Margins
With a decent Operating Margin value of 23.90%, BRM is doing good in the industry, outperforming 73.08% of the companies in the same industry.
In the last couple of years the Operating Margin of BRM has declined.
BRM's Gross Margin of 75.26% is fine compared to the rest of the industry. BRM outperforms 67.31% of its industry peers.
In the last couple of years the Gross Margin of BRM has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 23.9% | ||
| PM (TTM) | N/A | ||
| GM | 75.26% |
OM growth 3Y-0.56%
OM growth 5Y-4.29%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.73%
GM growth 5Y1.42%
2. Health
2.1 Basic Checks
BRM has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
The number of shares outstanding for BRM has been reduced compared to 1 year ago.
BRM has less shares outstanding than it did 5 years ago.
BRM has a worse debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 2.23 indicates that BRM is not a great score, but indicates only limited risk for bankruptcy at the moment.
BRM's Altman-Z score of 2.23 is in line compared to the rest of the industry. BRM outperforms 55.77% of its industry peers.
BRM has a debt to FCF ratio of 3.56. This is a good value and a sign of high solvency as BRM would need 3.56 years to pay back of all of its debts.
BRM has a better Debt to FCF ratio (3.56) than 61.54% of its industry peers.
A Debt/Equity ratio of 2.93 is on the high side and indicates that BRM has dependencies on debt financing.
The Debt to Equity ratio of BRM (2.93) is worse than 78.85% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.93 | ||
| Debt/FCF | 3.56 | ||
| Altman-Z | 2.23 |
ROIC/WACC1.32
WACC8.89%
2.3 Liquidity
A Current Ratio of 1.25 indicates that BRM should not have too much problems paying its short term obligations.
BRM's Current ratio of 1.25 is on the low side compared to the rest of the industry. BRM is outperformed by 67.31% of its industry peers.
A Quick Ratio of 1.15 indicates that BRM should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.15, BRM is in the better half of the industry, outperforming 63.46% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.25 | ||
| Quick Ratio | 1.15 |
3. Growth
3.1 Past
The earnings per share for BRM have decreased strongly by -84.80% in the last year.
The earnings per share for BRM have been decreasing by -24.57% on average. This is quite bad
Looking at the last year, BRM shows a small growth in Revenue. The Revenue has grown by 7.32% in the last year.
BRM shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 13.06% yearly.
EPS 1Y (TTM)-84.8%
EPS 3Y-46.63%
EPS 5Y-24.57%
EPS Q2Q%-1.76%
Revenue 1Y (TTM)7.32%
Revenue growth 3Y1.36%
Revenue growth 5Y13.06%
Sales Q2Q%7.54%
3.2 Future
Based on estimates for the next years, BRM will show a very strong growth in Earnings Per Share. The EPS will grow by 39.59% on average per year.
Based on estimates for the next years, BRM will show a decrease in Revenue. The Revenue will decrease by -4.01% on average per year.
EPS Next Y498.05%
EPS Next 2Y133.71%
EPS Next 3Y75.69%
EPS Next 5Y39.59%
Revenue Next Year-4.64%
Revenue Next 2Y-5.27%
Revenue Next 3Y-3.69%
Revenue Next 5Y-4.01%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 54.57, BRM can be considered very expensive at the moment.
The rest of the industry has a similar Price/Earnings ratio as BRM.
When comparing the Price/Earnings ratio of BRM to the average of the S&P500 Index (29.35), we can say BRM is valued expensively.
The Price/Forward Earnings ratio is 9.12, which indicates a very decent valuation of BRM.
86.54% of the companies in the same industry are more expensive than BRM, based on the Price/Forward Earnings ratio.
The average S&P500 Price/Forward Earnings ratio is at 22.10. BRM is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 54.57 | ||
| Fwd PE | 9.12 |
4.2 Price Multiples
BRM's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. BRM is cheaper than 78.85% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, BRM is valued cheaper than 90.38% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 9.05 | ||
| EV/EBITDA | 7.77 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
BRM's earnings are expected to grow with 75.69% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.11
PEG (5Y)N/A
EPS Next 2Y133.71%
EPS Next 3Y75.69%
5. Dividend
5.1 Amount
BRM has a Yearly Dividend Yield of 4.12%, which is a nice return.
BRM's Dividend Yield is rather good when compared to the industry average which is at 2.86. BRM pays more dividend than 86.54% of the companies in the same industry.
Compared to an average S&P500 Dividend Yield of 2.33, BRM pays a better dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.12% |
5.2 History
On average, the dividend of BRM grows each year by 11.67%, which is quite nice.
Dividend Growth(5Y)11.67%
Div Incr Years3
Div Non Decr Years3
5.3 Sustainability
The earnings of BRM are negative and hence is the payout ratio. BRM will probably not be able to sustain this dividend level.
BRM's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP-54.35%
EPS Next 2Y133.71%
EPS Next 3Y75.69%
FRA:BRM (3/7/2025, 7:00:00 PM)
57.3
+2.37 (+4.31%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners80.77%
Inst Owner ChangeN/A
Ins Owners0.07%
Ins Owner ChangeN/A
Market Cap116.28B
Analysts68.39
Price Target57.6 (0.52%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.12% |
Yearly Dividend2.22
Dividend Growth(5Y)11.67%
DP-54.35%
Div Incr Years3
Div Non Decr Years3
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)16.53%
Min EPS beat(2)13.54%
Max EPS beat(2)19.51%
EPS beat(4)4
Avg EPS beat(4)15.2%
Min EPS beat(4)1.78%
Max EPS beat(4)25.96%
EPS beat(8)7
Avg EPS beat(8)9.24%
EPS beat(12)11
Avg EPS beat(12)8.32%
EPS beat(16)14
Avg EPS beat(16)6.25%
Revenue beat(2)2
Avg Revenue beat(2)5.02%
Min Revenue beat(2)4.41%
Max Revenue beat(2)5.63%
Revenue beat(4)4
Avg Revenue beat(4)4.3%
Min Revenue beat(4)2.53%
Max Revenue beat(4)5.63%
Revenue beat(8)5
Avg Revenue beat(8)1.2%
Revenue beat(12)8
Avg Revenue beat(12)1.22%
Revenue beat(16)9
Avg Revenue beat(16)0.88%
PT rev (1m)-0.68%
PT rev (3m)1.35%
EPS NQ rev (1m)-9.13%
EPS NQ rev (3m)-17.68%
EPS NY rev (1m)-2.97%
EPS NY rev (3m)-4.19%
Revenue NQ rev (1m)-6.43%
Revenue NQ rev (3m)-7.9%
Revenue NY rev (1m)-3.65%
Revenue NY rev (3m)-2.45%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 54.57 | ||
| Fwd PE | 9.12 | ||
| P/S | 2.61 | ||
| P/FCF | 9.05 | ||
| P/OCF | 8.31 | ||
| P/B | 7.73 | ||
| P/tB | N/A | ||
| EV/EBITDA | 7.77 |
EPS(TTM)1.05
EY1.83%
EPS(NY)6.28
Fwd EY10.96%
FCF(TTM)6.33
FCFY11.04%
OCF(TTM)6.89
OCFY12.03%
SpS21.92
BVpS7.41
TBVpS-13.02
PEG (NY)0.11
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -9.66% | ||
| ROE | -54.78% | ||
| ROCE | 16.77% | ||
| ROIC | 11.77% | ||
| ROICexc | 13.97% | ||
| ROICexgc | 61.75% | ||
| OM | 23.9% | ||
| PM (TTM) | N/A | ||
| GM | 75.26% | ||
| FCFM | 28.87% |
ROA(3y)1.77%
ROA(5y)0.82%
ROE(3y)-2.38%
ROE(5y)-2.3%
ROIC(3y)10.96%
ROIC(5y)9.23%
ROICexc(3y)12.89%
ROICexc(5y)10.98%
ROICexgc(3y)70.34%
ROICexgc(5y)71.31%
ROCE(3y)15.62%
ROCE(5y)13.15%
ROICexcg growth 3Y-15.94%
ROICexcg growth 5Y3.18%
ROICexc growth 3Y7.54%
ROICexc growth 5Y19.82%
OM growth 3Y-0.56%
OM growth 5Y-4.29%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.73%
GM growth 5Y1.42%
F-Score3
Asset Turnover0.52
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.93 | ||
| Debt/FCF | 3.56 | ||
| Debt/EBITDA | 2.26 | ||
| Cap/Depr | 13% | ||
| Cap/Sales | 2.58% | ||
| Interest Coverage | 6.41 | ||
| Cash Conversion | 71.84% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.25 | ||
| Quick Ratio | 1.15 | ||
| Altman-Z | 2.23 |
F-Score3
WACC8.89%
ROIC/WACC1.32
Cap/Depr(3y)12.09%
Cap/Depr(5y)10.53%
Cap/Sales(3y)2.56%
Cap/Sales(5y)2.31%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-84.8%
EPS 3Y-46.63%
EPS 5Y-24.57%
EPS Q2Q%-1.76%
EPS Next Y498.05%
EPS Next 2Y133.71%
EPS Next 3Y75.69%
EPS Next 5Y39.59%
Revenue 1Y (TTM)7.32%
Revenue growth 3Y1.36%
Revenue growth 5Y13.06%
Sales Q2Q%7.54%
Revenue Next Year-4.64%
Revenue Next 2Y-5.27%
Revenue Next 3Y-3.69%
Revenue Next 5Y-4.01%
EBIT growth 1Y6.4%
EBIT growth 3Y0.79%
EBIT growth 5Y8.21%
EBIT Next Year276.32%
EBIT Next 3Y53.27%
EBIT Next 5Y27.81%
FCF growth 1Y10.2%
FCF growth 3Y-2.91%
FCF growth 5Y14.03%
OCF growth 1Y9.6%
OCF growth 3Y-2.14%
OCF growth 5Y13.49%